Malaria Vaccines Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Malaria Vaccines remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 334 matched trial records and 514 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07675785 | PfSPZ-LARC2 Vaccine(Sanaria) | Phase 2; Not yet recruiting | Sanaria, Inc. | Mali | Incidence of local AEs (Day 1 to Day 35); Incidence of systemic adverse events (Day 1 to Day 35) | 2028-07-15 |
| NCT07670377 | Midazolam Hydrochloride + GSK-3772701 | Phase 1; Not yet recruiting | GSK Plc | Geography not listed | Maximum observed concentration (Cmax) of MDZ (At 0 hours (h) (pre-dose) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 12, and 24…); Area under the concentration-time curve. from time 0 to the last measurable concentration [AUC(0-t)] of MDZ (At 0h (pre-dose) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 12, and 24 hours…) | 2026-08-27 |
| NCT07646353 | Intervention not normalized | Phase 1; Not yet recruiting | GSK Plc | Geography not listed | Number of participants with adverse events (AEs) overall and by severity (From Day 1 up to Day 364); Number of participants with serious adverse events (SAEs) overall and by severity (From Day -28 [informed consent form (ICF) signing] up to Day 364) | 2028-04-19 |
| JPRN-UMIN000061551 | Intervention not normalized | Not Applicable; 開始前/Preinitiation | Juntendo University | Geography not listed | 投薬前及び投薬開始後3日目のpeadiatric SOFAスコアの変化 (ΔpSOFA); Change in pSOFA score from baseline to Day 3 (Delta pSOFA) | 2030-12-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Exposure-Response Evaluation of IV Artesunate in Children With Severe Malaria (Phase 4): the indexed record reports -; Maximum Concentration (Cmax) of Dihydroartemisinin (DHA)(Median) = 4,361.09 ug/L (Full Range, 3,488.88 - 4,368.38); -.
- Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure (Phase 4): the indexed record reports Number of Patients Experiencing P. Vivax Recurrence = 48 Participants; -; Number of Patients Experiencing P. Vivax Recurrence = 11 Participants.
- Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial (Phase 3): the indexed record reports AE(drug related) = 16.0 Pts; AE(drug related) = 24.0 Pts; AE(drug related) = 13.0 Pts.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including PfSPZ-LARC2 Vaccine(Sanaria) (Phase 2), Midazolam Hydrochloride (Approved; GABAA receptor), GSK-3772701 (Phase 2). Company & Deal Intelligence records identify sponsor context for Sanaria, Inc., GSK Plc (GSK), Juntendo University. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Clinically meaningful endpoints paired with virologic or microbiologic measures.
- Evidence in immunocompromised, pediatric, pregnant and older populations.
- Resistance surveillance and combination strategies for prolonged infection.
- Coadministration, real-world effectiveness and implementation studies.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Malaria Vaccines has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
